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2Abstract: Vascular complications are what eventually threaten the lives of diabetic patients.
Here we show direct in vivo evidence that the interaction between advanced glycation
endproducts (AGE), the formation of which is accelerated during prolonged hyperglycemic
exposure, and a cell surface receptor for AGE (RAGE) is the major cause of such
complications. We created transgenic mice that overexpress human RAGE in vascular cells
and crossbred them with another transgenic line which develops insulin-dependent diabetes
early after birth. The resultant double transgenic mice exhibited accelerated kidney changes
compared with single transgenic littermates, and the nephropathy was ameliorated by an
inhibitor of AGE formation. The AGE-RAGE system will thus be a promising target for
overcoming diabetic complications.
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Background: Exposure of proteins to reducing sugers like glucose results in nonenzymatic
glycation which forms reversible Schiff bases and Amadori compounds [1]. A serie  of
further complex molecular earrangements then yield irreversible AGE [1]. In diabetes
mellitus (DM), prolonged hyperglycemia superdrives this reaction and AGE accumulate in
the circulating blood and in various tissues [1]. A hypothesis that interactions between
3AGE and receptor for AGE (RAGE) [2, 3] are the major causes of diabetic vascular
derangement has emerged from experiments with vascular endothelial cells (EC) [4, 5],
pericytes [6] and renal mesangial cells [7] in culture and from AGE- or soluble RAGE-
infusion studies in animals [8, 9]. To evaluate directly this hypothesis in vivo, we created
RAGE transgenic mice (RAGETg) and analyzed the renal changes in these mice following
the induction of diabetes.
Material and Methods:
1. Construction of transgenic mice and induction of diabetes. RAGETg was produced by
introducing a transgene that carryed human RAGE genomic DNA under the control of the
murine flk-1 promoter, which acts specifically in EC [10]. RAGETg was crossbred with
another transgenic mouse carrying human cDNA for inducible nitric oxide synthase (iNOS)
under the control of the insulin promoter (iNOSTg) [11].
2. Reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was isolated by
the guanidinium thiocyanate method and reverse-transcribed as described [12].
3. Isolation of EC and monocytes, and western blot analysis. EC from mouse renal cortex
and peripheral blood monocytes were isolated as described [12]. Proteins were extracted
from the cells and underwent western blot analyses as described [12].
4. Determination of AGE. Serum Ne -carboxymethyl-lysine (CML) and non-CML AGE
were differentially measured by a competitive ELISA as described [13].
Immunofluorescence analysis of the kidney sections was carried out with anti-CML and
anti-non-CML AGE antibodies [13] as described [14].
5. Albuminuria. Urinary albumin and creatinine levels were determined as described [15],
amd used to calculate the albumin : creatinine ratio.
6. Renal histology. The severity of the renal sclerosis was scored on an arbitrary scale from
40 to 4 [14]. The mean glomerular volume was determined as described [14, 15]. Periodic
acid-Schiff (PAS)-positive area in the mesangium was measured to quantify mesangial
expansion [16].
Results: We could successfully create 5 lines of RAGETg. Two lines of them, 102 and 103,
carrying high copy numbers of the transgene were used for subsequent experiments. RT-
PCR analysis with human RAGE-specific primers revealed active transcription of the
transgene in each line, and immunoblotting confirmed the overexpression of RAGE
proteins in whole kidney, renal EC and peripheral monocytes. Renal glomeruli of RAGETg
were positively stained for human RAGE in an EC pattern. Next, we employed a genetic
approach by which a diabetic state and advanced glycation as well would be most stably
induced. Viz, RAGETg was crossbred with another transgenic line-iNOSTg that
consistently develops insulin-dependent diabetes as early as 1 week after birth, yielding
four groups of littermates designated DoubleTg, iNOSTg, RAGETg, and non-transgenic
control. Blood analysis revealed sustained hyperglycemia, high HbA1c levels and the
progressive accumulation of non-CML AGE in the diabetic groups, but no significant
differences between DoubleTg and iNOSTg. Serum CML was marginally increased in the
diabetic groups.
     Diabetic renal complication is characterized by increased albuminuria, glomerular
hypertrophy and mesangial expansion as well as nephromegaly in the early phase [17]. In
its late phase, glomerulosclerosis and increased serum creatinine follow [17]. The urinary
albumin : creatinine ratio became significantly higher in DoubleTg than in the other groups
at 4 months. The microscopic lesions noted in the diabetic groups consisted of glomerular
cell proliferation, glomerular hypertrophy and mesangial expansion. DoubleTg showed
accelerated increases in glomerular cell proliferation, glomerular volume, and mesangial
5area and fraction in comparison with iNOSTg. Diffuse glomerulosclerosis progressed as the
mice aged in both groups. However, there was a conspicuous difference between DoubleTg
and iNOSTg in the severity of sclerosis, as evidenced by increased accumulation of PAS-
positive materials in the mesangial area of the former group of animals. Quantitative
examinations of at least 50 glomeruli per mouse revealed a significantly higher sclerosis
index in DoubleTg than in iNOSTg at 4 months of age. Immunostaining showed that
significant amounts of not only non-CML AGE but also CML accumulated in the
mesangial area in the diabetic mice, but not in non-diabetic mice. At 6 months of age, the
serum creatinine level of DoubleTg increased to 1.24 ± 0.07 mg/dl, being the highest
among the groups. Further, typical nodular lesions and hyaline arteriosclerosis were noted
at 8 months of age in DoubleTg.
     We then conducted an intervention study with OPB-9195, a thiazolidine derivative
that can inhibit AGE formation by blocking carbonyl groups on glycation intermediates.
When the mice had received OPB-9195 p.o. for 5 months, the serum non-CML AGE and
CML levels were reduced in diabetic groups, with the blood glucose and HbA1c being
essentially unaffected. The OPB-9195 treatment significantly suppressed the increase in
both serum creatinine and the sclerosis index of DoubleTg at 6 months of age.  
Conclusion: Overexpression of human RAGE gene in vascular cells has been demonstrated
to cause a significant acceleration of all the early- and late-phase indices of diabetic
nephropathy (Table 1), and the development of this complication was reversed by the
inhibition of AGE formation. Because circulating levels of AGE and their deposition in
renal glomeruli were essentially invariant between the diabetic animals carrying or not
carrying the RAGE transgene, the level of RAGE expression was considered to have rate-
limited the progression of diabetic nephropathy. The present study indicates that RAGE
6engagement by AGE plays an active role in the development of diabetic nephropathy, and
that the AGE-RAGE system is an effective target for intervention in this disease. Further,
there was no single animal model that develops renal changes imilar to those seen in
humans [18]. The double transgenic mice will serve as a most useful animal model for
studying the pathogenesis of diabetic kidney complications and for testing remedies.
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Stage
1. Early renal hypertrophy- 
    hyperfunction
2. Renal lesions 
    without clinical signs
3. Incipient diabetic 
    nephropathy
4. Proteinuria, clinical overt 
    diabetic nephropathy
5. End-stage renal failure
Chronology
Human DoubleTg
- 2 yrs -
Almost all 
in first 5 yrs
Typically after 
6 - 15 yrs
After 15-25 yrs
Final outcome, 
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4 - 6 mo
> 6 mo
Table 1. Chronological course of renal derangement in the present mouse model compared with type 1 diabetes patients
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